C

Cencora, Inc.

COR NYSE Industrials · Wholesale-Drugs, Proprietaries & Druggists' Sundries Conshohocken, PA www.cencora.com
$314.69
Mkt Cap 61.23B
As used herein, the terms Company, Cencora, we, us, or our refer to Cencora, Inc., a Delaware corporation. Cencora is one of the largest global pharmaceutical sourcing and distribution services compan…

As used herein, the terms Company, Cencora, we, us, or our refer to Cencora, Inc., a Delaware corporation. Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services (including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance) niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.

/100 Overall
Calculating score…
Running full analysis
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$332.77B
FCF TTM
-$3.80B
P/E RATIO
23.3x
Running full 6-factor analysis…